Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1995 Dec;54(12):991–994. doi: 10.1136/ard.54.12.991

Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis.

B Godeau 1, J L Mainardi 1, F Roudot-Thoraval 1, E Hachulla 1, L Guillevin 1, L T Huong Du 1, B Jarrousse 1, P Remy 1, A Schaeffer 1, J C Piette 1
PMCID: PMC1010066  PMID: 8546533

Abstract

OBJECTIVE--To determine the factors associated with the occurrence of Pneumocystis carinii pneumonia (PCP) in Wegener's granulomatosis (WG). METHODS--We retrospectively compared a group of 12 patients with WG and PCP (PCP group), with 32 WG patients without PCP followed over the same period in the same centres (control group). RESULTS--The mean delay of onset of PCP after the start of the immunosuppressive therapy was 127 (SD 128) days. Before treatment, the clinical and biological features of the two groups were similar, except for the mean lymphocyte count which was lower in the PCP group than in the control group (1060/mm3 v 1426/mm3; p = 0.04). During treatment, both groups were lymphopenic. There was a significant difference between the lowest absolute lymphocyte count in each group (244/mm3 in the PCP group v 738/mm3 in the control group; p = 0.001). During the first three months of treatment, the lymphocyte count was less than 600/mm3 at least once in 10 of the 12 patients in the PCP group and in 11 of the 32 patients in the control group (p < 0.01). The mean cumulative dose of cyclophosphamide was greater in the PCP group than in the control group at the end of both the second (1.55 mg/kg/day v 0.99 mg/kg/day; p = 0.05) and the third (1.67 mg/kg/day v 0.97 mg/kg/day; p = 0.03) months. However, in multivariate analysis, the only two factors independently and significantly associated with the occurrence of PCP were the pretreatment lymphocyte count (p = 0.018) and the lymphocyte count three months after the start of the immunosuppressive treatment (p = 0.014). CONCLUSIONS--The severity of lymphocytopenia before and during immunosuppressive treatment is the factor best associated with PCP in WG.

Full text

PDF
991

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradley J. D., Brandt K. D., Katz B. P. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum. 1989 Jan;32(1):45–53. doi: 10.1002/anr.1780320108. [DOI] [PubMed] [Google Scholar]
  2. Godeau B., Coutant-Perronne V., Le Thi Huong D., Guillevin L., Magadur G., De Bandt M., Dellion S., Rossert J., Rostoker G., Piette J. C. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994 Feb;21(2):246–251. [PubMed] [Google Scholar]
  3. Hoffman G. S., Kerr G. S., Leavitt R. Y., Hallahan C. W., Lebovics R. S., Travis W. D., Rottem M., Fauci A. S. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488–498. doi: 10.7326/0003-4819-116-6-488. [DOI] [PubMed] [Google Scholar]
  4. Hoffman G. S., Leavitt R. Y., Kerr G. S., Fauci A. S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992 Nov;35(11):1322–1329. doi: 10.1002/art.1780351113. [DOI] [PubMed] [Google Scholar]
  5. Jarrousse B., Guillevin L., Bindi P., Hachulla E., Leclerc P., Gilson B., Rémy P., Rossert J., Jacquot C., Nilson B [corrected to Gilson B. ]. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol. 1993 Nov-Dec;11(6):615–621. [PubMed] [Google Scholar]
  6. Kovacs J. A., Hiemenz J. W., Macher A. M., Stover D., Murray H. W., Shelhamer J., Lane H. C., Urmacher C., Honig C., Longo D. L. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984 May;100(5):663–671. doi: 10.7326/0003-4819-100-5-663. [DOI] [PubMed] [Google Scholar]
  7. Leavitt R. Y., Fauci A. S., Bloch D. A., Michel B. A., Hunder G. G., Arend W. P., Calabrese L. H., Fries J. F., Lie J. T., Lightfoot R. W., Jr The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990 Aug;33(8):1101–1107. doi: 10.1002/art.1780330807. [DOI] [PubMed] [Google Scholar]
  8. Liam C. K., Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus. 1992 Dec;1(6):379–385. doi: 10.1177/096120339200100607. [DOI] [PubMed] [Google Scholar]
  9. Porges A. J., Beattie S. L., Ritchlin C., Kimberly R. P., Christian C. L. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia. J Rheumatol. 1992 Aug;19(8):1191–1194. [PubMed] [Google Scholar]
  10. Rasmussen N., Petersen J., Ralfkiaer E., Avnstøm S., Wiik A. Spontaneous and induced immunoglobulin synthesis and anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis: relation to leukocyte subpopulations in blood and active lesions. Rheumatol Int. 1988;8(4):153–158. doi: 10.1007/BF00270453. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES